| Errors made in the design and conduct of a clinical trial can make it
impossible for the trial to provide a definitive answer about the effectiveness
of a new approach. Poor design can lead to the abandonment of promising
avenues of research that are based on sound basic scientific work and to
delays in the introduction of new treatments into the general practice of
oncology. AACR and ASCO have responded to this problem by designing a program
- Introduce clinical fellows and junior faculty in any oncology subspecialty
to the principles of good clinical trial design and give them the tools
they need to conduct clinical trials that will yield clear, definitive
- Expose young clinical scientists to the full spectrum of challenges
in clinical research, ranging from the use of conventional antineoplastic
agents to gene therapy, in the expectation that they will then want
to devote all or a portion of their future careers to some aspect of
clinical cancer research.
- Develop a cadre of well-trained, experienced clinical researchers
whose expertise will foster better clinical trial design and thereby
hasten the introduction of improved agents for cancer therapy and prevention
into everyday medical practice and patient care.
CONTINUING MEDICAL EDUCATION CREDITS
This activity has been planned and implemented in accordance with the
essential areas and policies of the Accreditation Council for Continuing
Medical Education through the joint sponsorship of the American Society
of Clinical Oncology and the American Association for Cancer Research.
The American Society of Clinical Oncology is accredited by the ACCME to
provide continuing medical education for physicians (ACCME provider number
The American Society of Clinical Oncology designates this continuing
medical education activity for up to 38.5 hours in Category 1 credit towards
the AMA Physician's Recognition Award. Each physician should claim only
those hours of credit that he/she actually spent in the educational activity.